



## Questcor Issues Corrected Dial-in Numbers for November 2nd Quarterly Conference Call

UNION CITY, Calif., Oct. 26, 2009 (GLOBE NEWSWIRE) -- In the news release, "Questcor Announces Third Quarter 2009 Earnings Release Date and Conference Call," issued on October 23, 2009 by Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR), the conference call dial-in numbers for domestic and international participants were transposed. Questcor will release financial results for the third quarter ended September 30, 2009 on Monday, November 2, 2009 after the market close. The Company will host a conference call and webcast on Monday, November 2, 2009 at 4:30 p.m. Eastern/1:30 p.m. Pacific to discuss the Company's third quarter and current corporate developments. The dial-in number for the conference call is 877-941-2332 for domestic participants and 480-629-9723 for international participants.

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will be available for seven days. This replay can be accessed by dialing 800-406-7325 for domestic callers and 303-590-3030 for international callers, both using passcode 4169702#. To access the live webcast of the call, go to Questcor Pharmaceuticals' website at [www.questcor.com](http://www.questcor.com). An archived webcast will also be available at [www.questcor.com](http://www.questcor.com).

### About Questcor

Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets H.P. Acthar<sup>®</sup> Gel (repository corticotropin injection). H.P. Acthar Gel ("Acthar") is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis ("MS") and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythamatosus. In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The Company also markets Doral<sup>®</sup> (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit [www.questcor.com](http://www.questcor.com).

CONTACT: Questcor Pharmaceuticals, Inc.  
Don Bailey  
510-400-0776  
[dbailey@Questcor.com](mailto:dbailey@Questcor.com)

EVC Group, Inc.  
Investors  
Doug Sherk

415-896-6820  
Media  
Christopher Gale  
646-201-5431